Assoc. Prof. Dr. Xiaoning wang | Medicine and Dentistry | Best Researcher Award
Assoc. Prof. Dr. Xiaoning wang, Department of Hematology, The First Affiliated Hospital of Xi’an Jiaotong University, China
Dr. Xiaoning Wang serves as the Deputy Director at The First Affiliated Hospital of Xi’an Jiaotong University. With over 17 years of medical expertise, Dr. Wang is an Associate Chief Physician specializing in hematopoietic stem cell transplantation and immunotherapy. 🧬✨ He has led notable research projects, including advancements in acute T-cell leukemia treatment and NK cell reconstruction. Dr. Wang has published extensively in renowned journals like Blood and Nature Communications 🩸📚 and holds multiple patents. A leader in the field, he is a key figure in various medical associations, driving innovation and collaboration in hematology. 🌐🎓
Publication Profile
Academic and Professional Background 🎓💼
Assoc. Prof. Dr. Xiaoning Wang has a rich medical career spanning over 17 years. He currently serves as an Associate Chief Physician (Jan 2017 – Present), where he oversees advanced hematology treatments and research. Previously, he worked as an Attending Physician (Mar 2012 – Dec 2016), gaining extensive expertise in patient care and clinical decision-making. His medical journey began as a Resident Doctor (July 2006 – Feb 2012), where he honed his foundational skills in diagnostics and treatment. Dr. Wang’s professional growth reflects his dedication to medical excellence and patient-focused innovation. 🏥🩺✨
Research and Innovations 🧬💡
Assoc. Prof. Dr. Xiaoning Wang has led impactful research in hematology and cell therapy. His notable projects include the National Key R&D Program on molecular typing and cell therapy for Acute T-Lymphocyte Leukemia (2022YFC2502700600000, ¥600k). He explored the effects of P53 gene demethylation on myeloma cell chemosensitivity under the National Natural Science Foundation of China (81600179, ¥180k). Other projects include studies on NK cell reconstruction in stem cell transplantation (2022SF-013, ¥60k) and the role of intestinal microbiota in GVHD prevention (2019JM-564, ¥30k). Dr. Wang also investigated drug resistance reversal in leukemia cells through estradiol-based innovations. 🔬✨
Publication Top Notes
- The novel HLA-C*14:02:01:33 allele identified by Pacific Biosciences HiFi sequencing in a Chinese individual.
- A regimen based on the combination of trimethoprim/sulfamethoxazole with caspofungin and corticosteroids as a first-line therapy for patients with severe non-HIV-related pneumocystis jirovecii pneumonia: a retrospective study in a tertiary hospital.
- Endogenous Aspergillus thermomutatus Endophthalmitis in a Patient With Myelodysplastic Syndrome.
- High levels of NK Cells in graft are associated with reduced febrile neutropenia after haploidentical peripheral blood stem cell transplantation.
- The latest edition of WHO and ELN guidance and a new risk model for Chinese acute myeloid leukemia patients.
- Bloody tears as initial manifestation of rhino-orbital mucormycosis.
- Pneumocystis jiroveci Pneumonia secondary to tyrosine kinase inhibitor with blinatumomab therapy: A case report.
- ADAR1 improved Treg cell function through the miR-21b/Foxp3 axis and inhibits the progression of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
- Integrative Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unveils Novel Prognostic Biomarkers in Multiple Myeloma.
- Acute myeloid leukemia secondary to acute B lymphoblastic leukemia treated with maintenance therapy in a child: A case report.
- Basiliximab for steroid-refractory acute graft-versus-host disease: A real-world analysis.